Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Ixazomib+ Lenalidomide + Dexamethasone	360
Overall Study	STARTED	Placebo + Lenalidomide + Dexamethasone	362
Overall Study	Intent-to-Treat (ITT) Population	Ixazomib+ Lenalidomide + Dexamethasone	360
Overall Study	Intent-to-Treat (ITT) Population	Placebo + Lenalidomide + Dexamethasone	362
Overall Study	Safety Population	Ixazomib+ Lenalidomide + Dexamethasone	361
Overall Study	Safety Population	Placebo + Lenalidomide + Dexamethasone	359
Overall Study	Response Evaluable Population	Ixazomib+ Lenalidomide + Dexamethasone	345
Overall Study	Response Evaluable Population	Placebo + Lenalidomide + Dexamethasone	348
Overall Study	COMPLETED	Ixazomib+ Lenalidomide + Dexamethasone	259
Overall Study	COMPLETED	Placebo + Lenalidomide + Dexamethasone	263
Overall Study	NOT COMPLETED	Ixazomib+ Lenalidomide + Dexamethasone	101
Overall Study	NOT COMPLETED	Placebo + Lenalidomide + Dexamethasone	99

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01564537/flow